Clinical Trial Update: Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009) [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated how renal impairment influences the pharmacokinetics, pharmacodynamics, safety, and tolerability of ertugliflozin in individuals wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (Steglatro) (ertugliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Impairment, Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2019-02-18